ILLUMINA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 105.3 USD | -0.22% |
|
-4.15% | -24.39% |
| 07-01 | RBC Lowers Price Target on Illumina to $242 From $249, Keeps Outperform Rating | MT |
| 07-01 | ANALYST RECOMMENDATIONS : Nvidia, Broadcom, Progressive, Draftkings, Moody's... |  |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows:
- product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.;
- sales of services (15.9%).
Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).
Calendar
2024-08-05
- Q2 2024 Earnings Call
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
105.3
USD
Average target price
147.3
USD
Spread / Average Target
+39.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.39% | 16.8B | |
| +0.91% | 204B | |
| +3.74% | 178B | |
| +28.89% | 156B | |
| +31.66% | 113B | |
| +1.18% | 64.26B | |
| +19.45% | 54.98B | |
| -3.44% | 47.44B | |
| -9.28% | 36.7B | |
| -0.10% | 34.84B |
- Stock Market
- Equities
- ILMN Stock
- News Illumina, Inc.
- RBC Lowers Price Target on Illumina to $242 From $249, Keeps Outperform Rating
